Today: 4 April 2026
Borsa Istanbul week ahead: BIST 100 eyes 14,000 after Friday rebound as banks and oil set the tone
22 February 2026
2 mins read

Borsa Istanbul week ahead: BIST 100 eyes 14,000 after Friday rebound as banks and oil set the tone

Istanbul, Feb 22, 2026, 11:46 TRT — The market is closed.

  • The BIST 100 closed out Friday at 13,934.06, recovering some lost territory following Thursday’s steep slide.
  • Banks drove the rebound, yet new survey data sent mixed messages about the real economy.
  • Monday opens with traders tracking the lira, crude prices, and keeping an eye on Thursday’s central bank reserves update.

The BIST 100 index finished Friday with a 0.94% gain, landing at 13,934.06 and stopping just short of 14,000 before markets resume on Monday. Reuters

The close call is catching attention—14,000 is now the line everyone’s eyeing, regardless of what they say about “levels”. Banks bounced back, with the sub-index up 1.85% Friday, erasing much of Thursday’s drop and thrusting lenders back out front as early-week guides. Borsa İstanbul

The Turkish lira barely budged heading into the weekend, holding near 43.82 per dollar on Friday’s close—enough stability to keep it out of the main headlines. With FX less volatile, equity market focus drifts back toward rates, earnings, and flows. Yahoo Finance

Friday’s data didn’t hand investors a clear “risk-on” or “risk-off” cue. The central bank survey put February’s capacity utilisation at 73.5%, down from 74.1% in January—meaning factories were tapping a bit less of their output potential. Hürriyet Daily News

Business sentiment in manufacturing picked up, with the Real Sector Confidence Index climbing 2.5 points to 104.1 in February, according to the central bank’s latest survey—a reading where optimism among firms outweighs pessimism. Hürriyet Daily News

Energy remains another factor investors are watching. Brent crude finished Friday at $71.76 per barrel, climbing over 5% for the week. Ongoing U.S.-Iran tensions continue to prop up prices with a geopolitical risk premium—a setup that muddies the outlook for inflation and adds pressure on oil importers such as Turkey. Reuters

Overseas action showed turbulence but little outright fear. U.S. equities climbed on Friday, buoyed by the Supreme Court’s move to overturn President Donald Trump’s global tariffs. Investors juggled that headline alongside conflicting economic readings on growth and inflation. Reuters

Thursday stands out as the first firm date on next week’s local calendar. According to Trading Economics, Turkey is set to publish its latest foreign exchange reserves update on Feb. 26. This weekly figure gives traders a snapshot of external buffers—often a signal for potential stress on the lira. Trading Economics

Volatility hasn’t gone far. After sliding 3.20% on Thursday, the BIST 100 snapped back Friday, a move that made clear just how fast sentiment can swing once banks and big industrials get in sync. Investing.com

The flip side isn’t hard to see. Factory utilisation keeps slipping, and a fresh surge in oil prices—or a firmer dollar—could easily stoke inflation concerns again, push up funding costs, and trigger another round of profit-taking in the market. TradingView

Traders are watching banks closely at the start of the week—will the sector pick up where Friday’s rally left off, or lose steam as investors weigh fresh growth signals and shifting global risk? The broader index has already moved sharply this year; it doesn’t take much to push it in either direction.

Stock Market Today

  • Innovent Biologics Shares Surge Amid Valuation Debate on SEHK
    April 4, 2026, 4:23 AM EDT. Innovent Biologics (SEHK:1801), a Hong Kong-listed biotech firm, has seen a strong share price rally with a 17.9% total return over the last month. Trading at HK$91.5, the company's price-to-sales (P/S) ratio stands at 10.7x, notably below the sector average of 13.6x and peers at 27x, signaling potential undervaluation. Its market cap is HK$158.8 billion, with revenues of CN¥13 billion and net income of CN¥813.6 million. The DCF (discounted cash flow) model estimates a fair value of HK$136.88 per share, suggesting room for further upside. Investors should weigh these positive signals against execution risks and the possibility that optimistic price targets may not be met. The stock's momentum comes as the company advances its global drug pipeline in a competitive biotech landscape.
Trump’s Iran deadline and Aldar’s $1bn Apollo notes: Week ahead on Abu Dhabi’s ADX
Previous Story

Trump’s Iran deadline and Aldar’s $1bn Apollo notes: Week ahead on Abu Dhabi’s ADX

Kruk’s 9% plunge puts Warsaw Stock Exchange in focus: what to watch for WIG20 this week
Next Story

Kruk’s 9% plunge puts Warsaw Stock Exchange in focus: what to watch for WIG20 this week

Go toTop